Menu
Recruiting NCT07093814

A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma

Phase I / Phase II Interventional Glioblastoma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: VRT106.
Who it may be relevant to
Registry conditions: Glioblastoma. Basic parameters: 18 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma

Overview

This study is an open-label, single-arm Phase I/II clinical trial with the primary objective of evaluating the safety, tolerability, and efficacy of VRT106 in patients with recurrent/progressive glioblastoma.

Detailed description

This study is an open-label, single-arm Phase I/II clinical trial comprising two parts: Phase I and Phase II. Phase I is a dose-escalation phase, with the primary objective of assessing the safety and tolerability of VRT106 at escalating doses in subjects with recurrent/progressive glioblastoma and confirming the Recommended Phase II Dose (RP2D). Phase II is a dose-expansion phase, in which subjects will receive VRT106 at the RP2D dose level, aiming to further evaluate the efficacy and safety of VRT106 in subjects with recurrent/progressive glioblastoma.

Interventions

  • Drug VRT106
    VRT106,intravenous

Primary outcome measures

  • Evaluate the safety and tolerability of escalating doses of VRT106 in Patients with recurrent/progressive glioblastoma [Time frame: About 2 years]
Secondary outcome measures (4)
  • Overall survival [Time frame: About 2 years]
  • Objective response rate [Time frame: About 2 years]
  • Distribution and shedding of VRT106 virus [Time frame: About 2 years]
  • Overall survival rate [Time frame: About 2 years]

Eligibility criteria

Inclusion criteria

  • Subjects voluntarily participate in the clinical study; fully understand and be informed about the study and sign the ICF; and are willing to follow and have the ability to complete all trial procedures.
  • Males and females are aged at 18-70 years (including borderline values) at the time of signing the ICF, male or female.
  • Diagnosed with recurrent/progressive glioblastoma.
  • Karnofsky Performance Status (KPS) score ≥60 within 28 days prior to the first administration of the study drug.
  • An expected survival time of≥3 months.
  • Have sufficient organ function.
  • Female patients of childbearing potential must have a negative serum pregnancy test result within 7 days prior to the first use of the study drug (if a false-positive pregnancy test result is due to non-pregnancy factors such as illness, further testing via ultrasound or other methods is required, and the investigator must confirm the absence of pregnancy before enrollment).
  • Subjects of childbearing potential (males and females) agree to use effective birth control with their partner from signing informed consent to at least 90 days after the last dose.

Exclusion criteria

  • Patients with extracranial metastases.
  • Previously received treatment with oncolytic viruses, gene therapy.
  • Subject has received treatment with other unlisted clinical investigational drugs/devices within 4 weeks prior to the first dose of VRT106.
  • Subject is known to have an allergic reaction to any of the components of VRT106.
  • Patients who can't have a cranial MRI scan.
  • Women who are breastfeeding.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

China · 11 centers
  • The First Affiliated Hospital of USTC — Hefei
  • Sanbo Brain Hospital Capital Medical University — Beijing
  • The Cancer Hospital Affiliated to Chongqing University — Chongqing
  • Nanfang Hospital, Southern Medical University — Guangzhou
  • Sun Yat-sen University Cancer Center — Guangzhou
  • Shenzhen Second People's Hospital — Shenzhen
  • The Fifth Affiliated Hospital of Sun Yat-sen University — Zhuhai
  • Guangxi Medical University Cancer Hospital — Nanning
  • … and 3 more centers

Identifiers

NCT: NCT07093814 · VRT106-CN02（INVIGOR-101）

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗